Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures (NCT07092605) | Clinical Trial Compass
By InvitationEarly Phase 1
Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures
United States150 participantsStarted 2024-11-01
Plain-language summary
The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity. The Secondary Objective: To assess the impact of these therapies on weight management practices and metabolic health.
Who can participate
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* New or existing AgelessRx patient
* Adults (aged 18-65)
* Any sex
* Any ethnicity
* BMI ≥ 20 kg/m\^2
* Interest in taking microdoses of semaglutide for health and longevity improvement with no intent to seek weight loss improvement.
Exclusion Criteria:
* Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s)
* History of bariatric surgery
* Use of other weight-loss medications currently or within the past 6 months
* Contraindications to semaglutide
* Significant psychiatric illness that may affect participation
* Pregnant or breastfeeding individuals
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in self-reported pain levels in participants microdosing GLP1s
Timeframe: 6 months
2
Concentration of complete blood cells, as a measure of immunological health, in participants microdosing GLP1s
Timeframe: 6 months
3
Concentration of basic metabolites (cholesterol, glucose, creatinine, sodium, potassium), as a measure of immunological health, in participants microdosing GLP1s
Timeframe: 6 months
4
Change in mood in participants microdosing GLP1s
Timeframe: 6 months
5
Change in heart rate variability in participants microdosing GLP1s
Timeframe: 6 months
6
Changes in sleep patterns in participants microdosing GLP1s
Timeframe: 6 months
7
Change in frequency of physical activity in participants microdosing GLP1s